- On May 18, 2026, Elliott Investment Management disclosed a significant stake in Bio-Rad Laboratories and began pressing the company to address what it describes as prolonged share price underperformance since late 2021.
- A central focus of Elliott’s campaign is Bio-Rad’s multibillion-dollar ownership stake in Sartorius, which it argues could be used more effectively to enhance shareholder value.
- We’ll now look at how Elliott’s activist involvement, particularly around Bio-Rad’s Sartorius stake, could reshape the company’s existing investment narrative.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
Bio-Rad Laboratories Investment Narrative Recap
To own Bio Rad today, you need to believe its life science and diagnostics franchises and large Sartorius stake can justify the current valuation despite modest growth and low returns on equity. Elliott’s new activist stake directly targets the “sum of the parts” gap and is now the key potential near term catalyst, while the biggest risk remains pressure on margins and earnings quality after recent losses and one off items.
The most relevant recent development alongside Elliott’s involvement is Bio Rad’s ongoing share repurchase program, with about 9.9% of shares bought back for roughly US$762.9 million since mid 2023. That capital allocation record now sits under a brighter spotlight, because any future decisions on the Sartorius holding, buybacks, or reinvestment could either support or weaken the case that the operating business is undervalued relative to its assets.
Yet beneath the activist headlines, investors should also be aware that rising regulatory costs and pricing pressure could quietly limit how much value is ultimately unlocked...
Read the full narrative on Bio-Rad Laboratories (it's free!)
Bio-Rad Laboratories' narrative projects $2.7 billion revenue and $226.1 million earnings by 2029.
Uncover how Bio-Rad Laboratories' forecasts yield a $293.00 fair value, in line with its current price.
Exploring Other Perspectives
By contrast, the most cautious analysts expected revenue of about US$2.7 billion and earnings near US$220.6 million by 2028, reminding you that views on Bio Rad’s risks and upside can differ sharply and may shift again as Elliott’s campaign and any Sartorius related decisions unfold.
Explore 2 other fair value estimates on Bio-Rad Laboratories - why the stock might be worth just $288.47!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Bio-Rad Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.
Contemplating Other Strategies?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com